Airway remodeling in asthma: what really matters.

Fehrenbach H, Wagner C, Wegmann M. · 2017

Read Airway remodeling in asthma: what really matters. by Fehrenbach H, Wagner C, Wegmann M. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5320023.txt.

Introduction

Heinz Fehrenbach, Christina Wagner, and Michael Wegmann reviewed airway remodeling in asthma in Cell and Tissue Research in 2017. Remodeling means lasting change in the size, make-up, and layout of the airway wall. Some change is normal, as lungs grow or heal after injury. Harmful change builds up under long injury and swelling, and leaves the wall altered for good.

The review asks four hard questions. How can remodeling be measured well and counted fairly? Can it start before any swelling begins? What is known when it follows swelling instead? And what do animal models, from simple creatures to primates, each teach? The authors call for studies matched to asthma subtypes, in both animals and patients. Fresh imaging tools, they hope, will let doctors watch remodeling in the living lung.

Catalog record

CREATORFehrenbach H, Wagner C, Wegmann M.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE111 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5320023

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Airway remodeling in asthma: what really matters By Heinz Fehrenbach, Christina Wagner, Michael Wegmann Published in: Cell and Tissue Research DOI: 10.1007/s00441-016-2566-8 ABSTRACT Airway remodeling is generally quite broadly defined as any change in composition, distribution, thickness, mass or volume and/or number of structural components observed in the airway wall of patients relative to healthy individuals. However, two types of airway remodeling should be distinguished more clearly: (1) physiological airway remodeling, which encompasses structural changes that occur regularly during normal lung development and growth leading to a normal mature airway wall or as an acute and transient response to injury and/or inflammation, which ultimately results in restoration of a normal airway structures; and (2) pathological airway remodeling, which comprises those structural alterations that occur as a result of either disturbed lung development or as a response to chronic injury and/or inflammation leading to persistently altered airway wall structures and function. This review will address a few major aspects: (1) what are reliable quantitative approaches to assess airway remodeling? (2) Are there any indications supporting the notion that airway remodeling can occur as a primary event, i.e., before any inflammatory process was initiated? (3) What is known about airway remodeling being a secondary event to inflammation? And (4), what can we learn from the different animal models ranging from invertebrate to primate models in the study of airway remodeling? Future studies are required addressing particularly pheno-/endotype-specific aspects of airway remodeling using both endotype-specific animal models and “endotyped” human asthmatics. Hopefully, novel in vivo imaging techniques will be further advanced to allow monitoring development, growth and inflammation of the airways already at a very early stage in life. INTRODUCTION With more than 241 million prevalent cases in 2013 (Global Burden of Disease Study 2013 Collaborators 2015), asthma is one of the most common lung diseases worldwide and it is expected that the number of people suffering from this chronic lung disease increases to about 300 million in 2025 (Croisant 2014). In 2013, asthma ranked 15th among all diseases worldwide with regard to years lived with the disability (YLD) over all age groups (Global Burden of Disease Study 2013 Collaborators 2015). Notably, asthma is most prevalent in children with highest YLDs observed in the age group 5–14 years (ranked 6th worldwide, even 2nd in the group of developed countries) (see http://vizhub.healthdata.org/gbd-compare/). On the basis of disability-adjusted life years, the impact of asthma is estimated being similar to other major chronic diseases such as diabetes or Alzheimer disease (Croisant 2014). Even though asthma is generally not seen as a major cause of death, the Global Burden of Disease Study 2013 reported a global age-standardized death rate of 8.0 per 100,000 in 2013, which is equivalent to breast cancer (7.4) or pedestrian road injuries (8.0). Hence, asthma remains among the top 50 causes of global years of life lost (GBD 2013 Mortality and Causes of Death Collaborators 2015). A brief search for the available literature in PubMed using the strategy “airway AND asthma AND (remodeling OR remodelling)” revealed that, in 1993, the first two papers falling into this category were published and that numbers slowly increased to 203 in 2007. Since then, the number of papers per year are on a relatively constant level of between 200 and 240, which represent only approx. 15% of all publications on “asthma AND airway”. Notably, among these publications, about 50–60 per year are review papers, i.e., 20–40% of all publications. To avoid carrying coals to Newcastle, in the present review we will not try to review everything already well reviewed by others (Elias 2000; Holgate et al. 2000; Saetta and Turato 2001; Jeffery 2004; Hogg 2004; Bai and Knight 2005; Boulet and Sterk 2007; Al-Muhsen et al. 2011; Martinez and Vercelli 2013; Saglani and Lloyd 2015). Instead, we will focus on some aspects related to a methodologically sound quantification as a prerequisite for the reliable assessment of airway remodeling and on what we can learn from invertebrate to primate animal models to better understand the mechanisms underlying physiological versus pathological remodeling. TODAY’S PERCEPTION OF BRONCHIAL ASTHMA: THE PHENOTYPE/ENDOTYPE CONCEPT The perception of bronchial asthma has fundamentally changed during the last decade. Consequently, the Global Initiative for Asthma (GINA) suggested a new definition of asthma: “Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation” (Reddel et al. 2015). The definition takes into account that during the last decade asthma turned out to be quite heterogeneous encompassing patients with different phenotypes (i.e., the entity of observable characteristics), which, however, exhibit overlap to variable degrees. Adult asthma was suggested to be not a single disease but a syndrome with one common feature being a variable expiratory airflow limitation (Lötvall et al. 2011; Wenzel 2006). The concept of asthma as a syndrome is also expected to be very helpful in pediatric asthma (Spycher et al. 2010; Lødrup Carlsen and Carlsen 2012). However, the characteristics used for the definition of the various phenotypes are not necessarily directly related to the underlying pathogenetic process(es). Aiming at the development of personalized therapies, i.e., therapeutic approaches targeting key elements of the causative pathomechanism(s), the concept of asthma endotypes was proposed with each endotype being the result of a specific molecular pathomechanism that is distinctly different from the other endotypes (Lötvall et al. 2011; Wenzel 2012; Agache et al. 2012). Until today, probably the (one and only) most clearly defined asthma endotype is the one termed the Th2 (T helper type 2)-high endotype, which is characterized by a T helper lymphocyte type 2-driven inflammation (Fahy 2015). Anti-inflammatory therapies targeting Th2 cytokines such as interleukin (IL)-4, IL-5 and IL-13 have consistently exhibited beneficial effects in adult patients diagnosed as Th2-high asthmatics on the basis of some emerging biomarkers related to the IL-13 response, such as periostin or FeNO (Bhakta and Woodruff 2011; Ingram and Kraft 2012; Fahy 2015; Fajt and Wenzel 2016). Efforts are being undertaken to reveal additional novel biomarkers that may help in identifying and distinguishing further endotypes (Zissler et al. 2016). The current phenotype/endotype concept of asthma has a strong focus on clinical and inflammatory characteristics and omitted aspects of airway remodeling, one important feature of asthma, as was recently emphasized (Saglani and Lloyd 2015). Today, it is unclear whether the differences in airway remodeling parameter values observed between individual patients define specific remodeling phenotypes and how these may relate to clinical or inflammatory phenotypes or are even linked to a specific endotype. DEFINING AIRWAY REMODELING IN ASTHMA: PHYSIOLOGICAL VERSUS PATHOLOGICAL PROCESSES Most review papers define airway remodeling quite broadly as any change in composition, distribution, thickness, mass or volume and/or number of structural components observed in the airway wall of patients relative to the airway wall of normal healthy individuals (Bergeron et al. 2009; Bai 2010; Hirota and Martin 2013). Changes have been described for various tissues in asthma patients, such as airway epithelium (e.g., epithelial shedding, goblet cell hyperplasia, basal membrane thickening), peribronchial interstitial tissue (e.g., subepithelial fibrosis), airway smooth muscle cells (e.g., hyperplasia and/or hypertrophy), nerve tissue (e.g.,

Read the complete text